Table 2.
Summary of drug‐based treatments in phase 3 clinical trials with sample size of more than thousand patients against severe acute respiratory syndrome coronavirus‐2
| Study identification number | Country | Sample size | Intervention assessed | Primary endpoint |
|---|---|---|---|---|
| NCT04292899 | Multicenter study; sponsor‐Gilead | 6000 | Remdesivir | The odds of ratio for improvement on a seven‐point Ordinal scale on day 14 |
| NCT04292730 | Multicenter study; sponsor‐Gilead | 1600 | Remdesivir | The odds of ratio for improvement on a seven‐point Ordinal Scale on Day 11 |
| NCT04315948 | Multicenter study; sponsor‐National Institute of France | 3000 | Remdesivir; lopinavir/ritonavir; interferon β‐1A; hydroxychloroquine | Percentage of subjects reporting each severity rating on a seven‐point ordinal scale on day 15 |
| NCT04324047 | France Sponsor‐ Assistance Publique‐Hôpitaux de Paris | 1000 | Immune modulator drugs | Overall survival at day 14 WHO progression scale COVID‐19 |
| NCT04322682 | Canada Sponsor‐Montreal heart institute | 6000 | Colchicine | Number of participants who die or require hospitalization due to COVID‐19 infection upto day 30 |
| ISRCTN83971151 Solidarity trial | Multicenter study Sponsor‐WHO | 100000 | Remdesivir, chloroquine or hydroxychloroquine, lopinavir plus ritonavir, and interferon‐beta | All‐cause mortality, subdivided by the severity of disease at the time of randomization, measured using patient records throughout the study |
| NCT04328012 | USA Sponsor‐ Bassett Healthcare | 4000 | Lopinavir/ritonavir; hydroxychloroquine sulfate; losartan | National Institute of Allergy and Infectious Diseases COVID‐19 Ordinal Severity Scale (NCOSS) at 60 d |
| NCT04345289 | Denmark Sponsor‐Thomas Benfield | 1500 | Convalescent anti‐SARS‐CoV‐2 plasma; sarilumab; baricitinib; hydroxychloroquine | All‐cause mortality or need of invasive mechanical ventilation at day 28 |
| NCT04358068 | USA Sponsor‐NIH | 2000 | Hydroxychloroquine + azithromycin | Proportion of participants who died from any cause or were hospitalized at day 21 |
| NCT04356495 | France Sponsor‐ University Hospital, Bordeaux | 1057 | Hydroxychloroquine; imatinib; favipiravir; telmisartan | Proportion of participants with an occurrence of hospitalization or death at day 14 |
| NCT04358003 | USA sponsor‐Marker Therapeutics AG | 2000 | Plasma adsorption cartridge | All‐cause mortality at day 28 |